BioCentury
ARTICLE | Product R&D

Addex's allosterics

Addex is addressing allosteric modulator complexities with research collaborations

February 5, 2015 8:00 AM UTC

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging partnerships with research institutions to fill in the mechanistic gaps around its candidate compounds before moving them into the clinic. The biotech hopes to buy both time and knowledge as it shores up finances and remodels its strategy for moving the pipeline forward.

In January, Addex announced its latest preclinical research partnership: a collaboration with the National Institute of Alcohol Abuse and Alcoholism (NIAAA) to evaluate the company's GABA B receptor positive allosteric modulator (PAM) ADX71441 in preclinical models of alcohol use disorder. ...